Suppr超能文献

溶栓治疗的急性心肌梗死患者再灌注临床标志物的预后价值

Prognostic value of clinical markers of reperfusion in patients with acute myocardial infarction treated by thrombolytic therapy.

作者信息

Pomés Iparraguirre H, Conti C, Grancelli H, Ohman E M, Calandrelli M, Volman S, Garber V

机构信息

Instituto de Cardiologia, Hospital Español, Buenos Aires, Argentina.

出版信息

Am Heart J. 1997 Oct;134(4):631-8. doi: 10.1016/s0002-8703(97)70045-0.

Abstract

Patients who cannot be reperfused after thrombolytic therapy have a high mortality rate. Noninvasive clinical markers of reperfusion have been widely studied, yet their prognostic significance remains unclear. To assess the prognostic value of commonly used noninvasive clinical markers of early reperfusion we studied 327 patients who received intravenous thrombolytic treatment (1.5 MU streptokinase in 1 hour or 100 mg alteplase in 3 hours) within 6 hours of acute infarction. Successful clinical reperfusion (SCR) was defined as the presence of at least two of the following criteria at 2 hours after thrombolytic treatment: (1) significant relief of pain (a 5-point reduction on a 1 to 10 subjective scale), (2) > or =50% reduction of sum of ST segment elevation, and (3) abrupt initial increase of creatine kinase levels (more than twofold over the upper-normal or baseline elevated values). Clinical variables that were significantly associated by univariate analysis were tested by multivariate analysis to obtain independent predictors of 30-day mortality rate. SCR was present in 210 (64%) patients (group 1), and absent in 117 (36%) patients (group 2). The groups were similar for most baseline characteristics, although group 2 patients were slightly older (mean 60 vs 57 years, p < 0.02). Thirty-day outcomes for group 2 patients compared with group 1 patients were heart failure in 23.1% and 10.5% (p < 0.005), progression to cardiogenic shock in 12.8% and 0.5%, (p < 0.00001), and death in 16.2% and 3.8% (p < 0.0001), respectively. By multivariate analysis the Killip class at admission (p < 0.00001), the absence of SCR (p = 0.017), anterior infarct location (p = 0.021), and age (p = 0.03) were independent predictors of mortality rate, and sex (p = 0.051) had borderline significance. The absence of SCR defined a group of patients with significantly higher mortality rate (odds ratio 4.89, 95% confidence interval 2.07 to 11.57). Three simple noninvasive clinical criteria of successful reperfusion may be used to identify a group of patients with poor prognosis after thrombolytic therapy in whom alternative strategies could be applied.

摘要

溶栓治疗后无法实现再灌注的患者死亡率很高。再灌注的非侵入性临床标志物已得到广泛研究,但其预后意义仍不明确。为评估常用的早期再灌注非侵入性临床标志物的预后价值,我们研究了327例在急性梗死6小时内接受静脉溶栓治疗(1小时内静脉滴注150万单位链激酶或3小时内静脉滴注100毫克阿替普酶)的患者。成功的临床再灌注(SCR)定义为溶栓治疗后2小时出现以下至少两条标准:(1)疼痛显著缓解(主观评分从1至10分降低5分),(2)ST段抬高总和降低≥50%,(3)肌酸激酶水平突然开始升高(超过正常上限或基线升高值两倍以上)。通过单因素分析显著相关的临床变量进行多因素分析,以获得30天死亡率的独立预测因素。210例(64%)患者出现SCR(第1组),117例(36%)患者未出现SCR(第2组)。两组的大多数基线特征相似,尽管第2组患者年龄稍大(平均60岁对57岁,p<0.02)。与第1组患者相比,第2组患者30天的结局分别为心力衰竭23.1%对10.5%(p<0.005)、进展为心源性休克12.8%对0.5%(p<0.00001)以及死亡16.2%对3.8%(p<0.0001)。通过多因素分析,入院时的Killip分级(p<0.00001)、未出现SCR(p=0.017)、前壁梗死部位(p=0.021)和年龄(p=0.03)是死亡率的独立预测因素,性别(p=0.051)具有临界显著性。未出现SCR定义了一组死亡率显著更高的患者(比值比4.89,95%置信区间2.07至11.57)。成功再灌注的三条简单非侵入性临床标准可用于识别溶栓治疗后预后不良的一组患者,对此可应用替代策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验